Tropheryma whipplei
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA12312 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| CAAG02.dat.gz | Other | |||
| CAAG02.fasta.gz | Fasta.gz | |||
| CAAG02.master.dat | Other | |||
| CAAH02.dat.gz | Other |
Items per page: 5 1 - 5 of 52 |
Similar Datasets
Project description:Causative agent of Whipple's disease.
| PRJNA95 | ENA
Project description:Causative agent of Whipple's disease.
| PRJNA354 | ENA
Project description:This SuperSeries is composed of the following subset Series: GSE16180: Bone-marrow derived macrophages response to the Whipple's disease agent, Tropheryma whipplei GSE20207: Wild-type bone-marrow derived macrophages response to Escherichia coli lipopolysaccharide (LPS) GSE20208: Interleukin-16-knock-out bone-marrow derived macrophages response to Escherichia coli lipopolysaccharide (LPS) GSE20209: Interleukin-16-knock-out bone-marrow derived macrophages response to the Whipple's disease agent, Tropheryma whipplei Refer to individual Series
2010-11-08 | E-GEOD-20210 | biostudies-arrayexpress
Project description:Tropheryma whipplei endocarditis differs from classic Whipple disease, which primarily affects the gastrointestinal system. We diagnosed 28 cases of T. whipplei endocarditis in Marseille, France, and compared them with cases reported in the literature. Specimens were analyzed mostly by molecular and histologic techniques. Duke criteria were ineffective for diagnosis before heart valve analysis. The disease occurred in men 40-80 years of age, of whom 21 (75%) had arthralgia (75%); 9 (32%) had valvular disease and 11 (39%) had fever. Clinical manifestations were predominantly cardiologic. Treatment with doxycycline and hydroxychloroquine for at least 12 months was successful. The cases we diagnosed differed from those reported from Germany, in which arthralgias were less common and previous valve lesions more common. A strong geographic specificity for this disease is found mainly in eastern-central France, Switzerland, and Germany. T. whipplei endocarditis is an emerging clinical entity observed in middle-aged and older men with arthralgia.
| S-EPMC3837638 | biostudies-literature
Project description:Global Transcriptome Analysis of Tropheryma whipplei in Response to Temperature Stresses
| PRJNA93841 | ENA
Project description:Comparative genomic analysis of T.whipplei strains reveals that diversity is mainly related to the WiSP proteins
| PRJNA100211 | ENA
Project description:Tropheryma whipplei Detection by Nanopore Sequencing
| PRJNA754208 | ENA
Project description:Metagenomic sequencing Analysis two genome of Tropheryma whipplei from China
| PRJNA831609 | ENA
Project description:Molecular Basis of Tropheryma whipplei Doxycycline Susceptibility Examined by Transcriptional Profiling
| PRJNA97009 | ENA
Project description:Whipple's disease is considered a rare chronic disease with a broad spectrum of clinical manifestations. Several antibiotics have been used for the treatment of this disease, and the current reference treatment was determined empirically on the basis of only a few clinical observations. Patients should be treated for months, and many relapse after antibiotic withdrawal. We report here the first extensive study on the susceptibilities of three reference strains of Tropheryma whipplei to antibiotic in cell culture by using a real-time PCR assay as previously described. We found that doxycycline, macrolides, ketolides, aminoglygosides, penicillin, rifampin, teicoplanin, chloramphenicol, and trimethoprim-sulfamethoxazole were active, with MICs ranging from 0.25 to 2 microg/ml. Vancomycin was somewhat active at an MIC of 10 microg/ml. We found heterogeneity in the susceptibility to imipenem, with one strain being susceptible and the two other strains being resistant. Cephalosporins, colimycine, aztreonam, and fluoroquinolones were not active. We also demonstrated that a combination of doxycycline and hydroxychloroquine was bactericidal. This combination has been shown to be active in the treatment of patients suffering from chronic infections with Coxiella burnetii, a bacterium that is also found intracellularly in acidic vacuoles. We believe, then, that this combination therapy should be further evaluated in clinical trials for the treatment of Whipple's disease.
| S-EPMC353111 | biostudies-literature